CATALENT
CTLTNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CTLT. That does not mean none is planned.
Get an email about CTLT's next catalysts
Track CATALENT (CTLT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
MELT-300 sublingual tablet
Cataract
Ademetionine tablet
Intrahepatic Cholestasis Associated With Alcoholic Liver Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MELT-300 sublingual tablet | Phase 3 | Cataract | - | - |
Ademetionine tablet | Phase 3 | Intrahepatic Cholestasis Associated With Alcoholic Liver Disease | - | - |
Frequently asked questions
What is in CATALENT's drug pipeline?β
CatalystAlert tracks 2 drug candidates in CATALENT's (CTLT) pipeline across Phase 3. Its lead program is Ademetionine tablet (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CATALENT's next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for CATALENT (CTLT) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track CTLT biotech catalysts?β
Add CTLT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CATALENT's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
